Atypical Myeloproliferative Disorders: Diagnosis and Management

Tefferi, Ayalew; Elliott, Michelle A.; Pardanani, Animesh
April 2006
Mayo Clinic Proceedings;Apr2006, Vol. 81 Issue 4, p553
Academic Journal
Myeloid disorders constitute a subgroup of hematological malignancies that is separate from lymphoid disorders. The World Health Organization system for classification of tumors of the hematopoietic system divides myeloid disorders into acute myeloid leukemia and chronic myeloid disorders based on the presence or absence, respectively, of acute myeloid leukemia — defining morphological and cytogenetic features including the presence of 20% or more myeloblasts in either the bone marrow or the peripheral blood. A recently proposed semimolecular classification system for chronic myeloid disorders recognizes 3 broad categories: the myelodysplastic syndrome, classic myeloproliferative disorders (MPD), and atypical MPD. Classic MPD includes polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, and chronic myeloid leukemia. Both myelodysplastic syndrome and BCR/ABL-negative classic MPD were previously discussed as part of the current ongoing symposium on hematological malignancies. The current review focuses on the diagnosis and treatment of both molecularly defined and clinicopathologically assigned categories of atypical MPD: chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, chronic neutrophilic leukemia, chronic basophilic leukemia, chronic eosinophilic leukemia, idiopathic eosinophilla including hypereosinophilic syndrome, systemic mastocytosis, unclassified MPD, and eosinophilic/mast cell disorders associated with mutations of platelet-derived growth factor receptors α (PDGFRA) and β (PDGFRB), FGFR1, and KIT.


Related Articles

  • JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Kilpivaara, O.; Levine, R. L. // Leukemia (08876924);Dec2008 Supplement, Vol. 22, pP106 

    Although it has long been known that the myeloproliferative neoplasms (MPN) polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are clonal hematopoietic stem-cell disorders, for many years the genetic basis for these disorders was elusive. A new era in MPN...

  • Chapter 12: Chronic Myeloproliferative Disorders. Finnegan, Kathy // Hematology in Practice;2007, p187 

    Chapter 12 of the book "Hematology in Practice" is presented. It focuses on chronic myeloproliferative disorders (CMPD). It describes the clinical features and symptoms of chronic myelogenous leukemia (CML), pathophysiology, and laboratory diagnosis. It discusses the link between erythroid...

  • Chronic Myeloproliferative Disorders: A Rarest Case with Oral Manifestations and Dental Management. Ruparelia, Pritesh B.; Ruparelia, Kosha Pritesh; Shirolkar, Rajan; Tripaith, Anurag // Journal of Indian Academy of Oral Medicine & Radiology;Apr-Jun2012, Vol. 24 Issue 2, p155 

    Chronic myeloproliferative disorders (CMPD) are rarest hematological disorders (malignant myeloid neoplasms). The three most common chronic myeloproliferative disorders are polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. Clinical manifestations (including oral...

  • Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Tefferi, A.; Vardiman, J. W. // Leukemia (08876924);Dec2008 Supplement, Vol. 22, pP14 

    The 2001 World Health Organization (WHO) treatise on the classification of hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of myeloid neoplasms that includes the four classic myeloproliferative disorders (MPDs) — chronic myelogenous leukemia,...

  • The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Orazi, A.; Germing, U. // Leukemia (08876924);Dec2008 Supplement, Vol. 22, pP53 

    The 2001 World Health Organization (WHO)-sponsored classification of hematopoietic tumors has, for the first time, clearly defined a group of rare myeloid neoplasms termed myelodys-plastic/myeloproliferative diseases (MDS/MPDs). This group includes three main entities, chronic myelomonocytic...

  • Usefulness of Measurement of Reticulated Platelets for Diagnosis of Idiopathic Thrombocytopenic Purpura. Sakakura, Miho; Wada, Hideo; Abe, Yasunori; Nishioka, Junji; Tomatsu, Hiroaki; Hamaguchi, Yukio; Oguni, Shinichiro; Shiku, Hiroshi; Nobori, Tsutomu // Clinical & Applied Thrombosis/Hemostasis;Jul2005, Vol. 11 Issue 3, p253 

    Reticulated platelets (RP) and large platelets (LP) were measured by an automated hematology analyzer (modified R-2000) in 287 healthy volunteers and 131 patients with thrombocytopenia or thrombocytosis, RP was significantly higher in patients with idiopathic thrombocytopenic purpura (ITP),...

  • The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Smedley, Damian; Hamoudi, Rifat; Clark, Jeremy; Warren, William; Abdul‐Rauf, Munah; Somers, Gino; Venter, Deon; Fagan, Kerry; Cooper, Colin; Shipley, Janet // Human Molecular Genetics;Apr98, Vol. 7 Issue 4, p637 

    Studies an atypical myeloproliferative disorder involving eosinophilia, a high incidence of T-cell non-Hodgkin's lymphoma and rapid progression to myeloid leukemia. Fusion of the fibroblast growth factor receptor 1 gene to a novel gene RAMP; Candidate gene for X-linked mental retardation.

  • A Case of Philadelphia Chromosome Positive Myeloproliferative Neoplasm in a Pregnant Woman with Unusual Primary Myelofibrosis Features. Koshy, Jason; Alperin, Jack; Jana, Bagi; Markowitz, Avi; You-Wen Qian // Case Reports in Hematology;2013, p1 

    Myeloproliferative neoplasms (MPNs) are traditionally separated into BCR-ABL-positive chronic myeloid leukemia (CML), and BCR-ABL-negative MPNs including primary myelofibrosis (PMF), essential thrombocythemia (ET), and so forth. One of the diagnostic requirements for PMF and ET is the absence of...

  • Kinase drug discovery approaches in chronic myeloproliferative disorders. Kumar, C.; Purandare, A. V.; Lee, F. Y.; Lorenzi, M. V. // Oncogene;6/18/2009, Vol. 28 Issue 24, p2305 

    Myeloproliferative disorders (MPDs) are clonal malignancies that arise from hematopoietic progenitors and characterized by overproduction of mature, functional blood cells. These disorders can be broadly characterized into Philadelphia chromosome-positive (Ph(+)) or negative (Ph(−))...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics